Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:23 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 75 matching trials from the live ClinicalTrials.gov search.

Filters: Sponsor: Vanda Pharmaceuticals Clear all

Conditions: Bipolar I Disorder, Schizophrenia
Interventions: Iloperidone; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Marlton, New Jersey

Conditions: Motion Sickness
Interventions: Tradipitant; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Coronavirus Infection
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: New York, New York

Conditions: Bipolar Disorder
Interventions: iloperidone; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Healthy Volunteers
Interventions: Tasimelteon, Fluvoxamine; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Palmoplantar Pustulosis
Interventions: Imsidolimab, Placebo; Biological · Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 19
States / cities: Birmingham, Alabama • Phoenix, Arizona • Encino, California + 15 more

Conditions: Generalized Pustular Psoriasis
Interventions: Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab, Standard of Care (SOC), Imsidolimab 750 mg IV/200 mg SC; Drug · Other
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more

Conditions: Healthy Volunteers
Interventions: Tasimelteon, Rosiglitazone, Midazolam; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Nausea and Vomiting, Obesity
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 280 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 10
States / cities: Los Angeles, California • San Diego, California • San Jose, California + 7 more

Conditions: Jet Lag Disorder
Interventions: Transmeridian travel across multiple time zones; Other
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 119 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Santa Monica, California • Chevy Chase, Maryland

Conditions: Ichthyosis
Interventions: Imsidolimab, placebo; Drug · Biological
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 12 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 7
States / cities: Palo Alto, California • New Haven, Connecticut • Miami, Florida + 4 more

Conditions: Schizophrenia
Interventions: Iloperidone crystalline formulation, Iloperidone microparticle formulation, Oral iloperidone; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Glendale, California • Philadelphia, Pennsylvania

Conditions: Healthy
Interventions: Tasimelteon Oral Capsule, Tasimelteon Oral Suspension; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Conditions: Relapsed or Refractory Hematologic Malignancies
Interventions: Trichostatin A; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Lafayette, Indiana • Hackensack, New Jersey + 1 more

Conditions: Circadian Rhythm Sleep Disorders
Interventions: VEC-162; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Boston, Massachusetts • Detroit, Michigan

Conditions: Allergic Conjunctivitis
Interventions: VSJ-110, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Onychomycosis of Toenail
Interventions: Trichostatin A; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Fremont, California • Denver, Colorado • New Brighton, Minnesota + 2 more

Conditions: Schizophrenia
Interventions: Iloperidone; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 3
States / cities: Garden Grove, California • Gaithersburg, Maryland • Marlton, New Jersey

Conditions: Non-24-Hour Sleep-Wake Disorder
Interventions: tasimelteon, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 22
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 19 more

Conditions: Idiopathic Gastroparesis, Diabetic Gastroparesis, Gastroparesis
Interventions: Tradipitant, Placebo, Open Label Tradipitant; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 979 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 36
States / cities: Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 30 more

Conditions: Gastroparesis, Diabetic Gastroparesis
Interventions: Tradipitant; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
U.S. locations: 15
States / cities: Maitland, Florida • Tampa, Florida • Wauconda, Illinois + 12 more

Conditions: Sleep Disturbances in Smith-Magenis Syndrome
Interventions: Data collection of sleep disturbances in individuals with SMS; Other
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 3 Years to 65 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2030
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Healthy Volunteer
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Healthy
Interventions: VHX-896; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Springfield, Missouri

Search by objective public record fields.

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection

Iloperidone in Mixed States of Bipolar Disorder

Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis

Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP

A Study to Assess the Effect Tasimelteon on the Cytochrome P450 3A4 and 2C8 Enzymes in Healthy Subjects

A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use

An Observational Study to Investigate the Effects of Rapid Transmeridian Travel

A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis

Safety, Tolerability, and Pharmacokinetics of Iloperidone Depot in Schizophrenic Patients

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies

Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies

Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis

A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder

Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis

Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis

Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Food Effect Study of VHX-896 in Healthy Volunteers